

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+2.59%
-1.17%
+0.23%
EXEL
Exelixis
$38.72
Strengths

Trading below its fair value

Upgraded on attractively valued

Outperform the market
Risk Analysis

Earnings are forecast to decrease
Chart
$40.56 (-4.54%)
$37.26 (+3.92%)
$42.22 (-8.29%)
$35.8 (+8.16%)
EXEL has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

EXEL overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Trading below its fair value

Earnings are forecast to decrease

Outperform the market
![]()
EXEL Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
EXEL Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayEXEL Earnings
The TTM reflects 12-month period, providing review of EXEL financial performance.
The company financial health has moderately improved over the past year
Financial Score
RVMD
54.51
+1.95%
BNTX
105.66
+0.87%
AMGN
292.20
-0.39%
AGEN
4.16
-0.96%
What is EXEL current stock price?
What are EXEL stock strengths?
What risks are associated with EXEL stock?
When is EXEL next earnings report?
What is EXEL market cap and volume?
What is EXEL's current Stock IQ?
Should I buy EXEL stock right now?
Is EXEL a Strong Buy right now?
What does a 'Strong Buy' rating mean for EXEL?
What does a 'Strong Sell' rating mean for EXEL?
What factors influence EXEL's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+2.59%
-1.17%
+0.23%
EXEL
Exelixis
Current Price
$38.72
Stock Insights
Strengths

Trading below its fair value

Upgraded on attractively valued

Outperform the market
Risk Analysis

Earnings are forecast to decrease
Linked to EXEL
RVMD
54.51
+1.95%
BNTX
105.66
+0.87%
AMGN
292.20
-0.39%
AGEN
4.16
-0.96%
Chart
$40.56 (-4.54%)
$37.26 (+3.92%)
$42.22 (-8.29%)
$35.8 (+8.16%)
EXEL Analysts Opinion
EXEL Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Trading below its fair value

Earnings are forecast to decrease

Outperform the market
![]()
EXEL Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
EXEL Street view is bullish and have positive views on the near-term outlook
EXEL has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Average key support and resistance price levels.
EXEL Earnings
The TTM data reflects the most recent 12-month period, providing overview of EXEL financial performance.
EXEL Financial Health
The company financial health has moderately improved over the past year
Financial Score
EXEL Latest Analysis
Leerink Partners Upgrades Exelixis (EXEL). Fintel reports that on October 21 2025 Leerink Partners upgraded their outlook for Exelixis (NasdaqGS:EXEL) from Market Perform to Outperform. Analyst Price Forecast Suggests 30.87% Upside
Tue Oct 21, 2025
Exelixis (EXEL) Loses 12% on Cancer Treatment Trial Results. We recently published 10 Stocks With Massive Losses. AI Stocks Not Spared. Exelixis Inc. (NASDAQ:EXEL) is one of the worst performers on Monday. Exelixis tumbled by 12 percent on Monday to close at $34.54 apiece as unimpressed investors soured on the results of its phase 3 trial for the study of Zanzalintinib for colon cancer. [….]
Tue Oct 21, 2025
Top 3 Health Care Stocks Youll Regret Missing In October. The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator which compares a stock’.s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’.s price action it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below
Tue Oct 21, 2025
Validea John Neff Strategy Daily Upgrade Report - 10/21/2025. The following are todays upgrades for Valideas Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.EXELIXIS INC (EXEL) is
Tue Oct 21, 2025
Exelixis Enters Oversold Territory (EXEL). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which me
Mon Oct 20, 2025
Exelixis shares fall after mixed cancer trial results.
Mon Oct 20, 2025
The Ultimate Biotech Stock to Buy With $50 Right Now. Key PointsShares of mid-cap oncology specialist Exelixis are worth about $39 each right now.
Tue Oct 14, 2025
EXEL Makes Notable Cross Below Critical Moving Average. In trading on Thursday shares of Exelixis Inc (Symbol: EXEL) crossed below their 200 day moving average of $38.49 changing hands as low as $38.27 per share. Exelixis Inc shares are currently trading off about 0.2% on the day. The chart below shows the one year performance of
Thu Oct 9, 2025
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.
Thu Oct 9, 2025
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.
Wed Oct 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
EXEL Stock trends
EXEL Stock performance
EXEL Stock analysis
EXEL investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.